Molecular characterization and clinical epidemiology of HCV in District Dir (Lower), Pakistan

[1]  J. Ahmed,et al.  Molecular characterization of Hepatitis C virus 3a in Peshawar , 2016, BMC Infectious Diseases.

[2]  M. Ilyas,et al.  Chemiluminescent microparticle immunoassay based detection and prevalence of HCV infection in district Peshawar Pakistan , 2014, Virology Journal.

[3]  Aziz Ahmed,et al.  Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan , 2011, Virology Journal.

[4]  S. Hassan,et al.  HCV genotype distribution and possible transmission risks in Lahore, Pakistan. , 2010, World journal of gastroenterology.

[5]  M. Idrees,et al.  Molecular epidemiology of Hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan , 2010, Virology Journal.

[6]  M. Idrees,et al.  The changing epidemiology pattern and frequency distribution of hepatitis C virus in Pakistan. , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[7]  Y. Waheed,et al.  Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. , 2009, World journal of gastroenterology.

[8]  S. Vermund,et al.  Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. , 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  S. Riazuddin,et al.  Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission , 2008, BMC infectious diseases.

[10]  M. Khalid,et al.  High prevalence of hepatitis C virus infection in the largest province of Pakistan , 2008, Journal of digestive diseases.

[11]  S. Mehmood,et al.  Awareness among barbers about health hazards associated with their profession. , 2008, Journal of Ayub Medical College, Abbottabad : JAMC.

[12]  N. Raja,et al.  Epidemiology of hepatitis C virus infection in Pakistan. , 2008, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[13]  Z. Abbas,et al.  HELICOBACTER PYLORI, HEPATITIS VIRUSES A, C, E, ANTIBODIES AND HBsAg - PREVALENCE AND ASSOCIATED RISK FACTORS IN PEDIATRIC COMMUNITIES OF KARACHI. , 2007, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[14]  M. Asgher,et al.  An evidence of high prevalence of Hepatitis C virus in Faisalabad, Pakistan. , 2007, Saudi medical journal.

[15]  V. Turhan,et al.  Investigation of the genotype distribution of hepatitis C virus among Turkish population in Turkey and various European countries. , 2005, Chinese Medical Journal.

[16]  M. Mizokami,et al.  Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients , 2005, Archives of Virology.

[17]  N. Khokhar,et al.  General seroprevalence of hepatitis C and hepatitis B virus infections in population. , 2004, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[18]  S. Hamid,et al.  PSG consensus statement on management of hepatitis C virus infection--2003. , 2004, JPMA. The Journal of the Pakistan Medical Association.

[19]  N. Janjua,et al.  Knowledge and practices of barbers about hepatitis B and C transmission in Rawalpindi and Islamabad. , 2004, JPMA. The Journal of the Pakistan Medical Association.

[20]  Y. Sung,et al.  Optimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA Immunization , 2003, Journal of Virology.

[21]  Jafri Sm.  Hepatitis C virus - the Pakistani perspective. , 2003 .

[22]  S. Jafri.  Hepatitis C virus - the Pakistani perspective. , 2003, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[23]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002 .

[24]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002, Hepatology.

[25]  J. Albrecht,et al.  Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin , 2002, Hepatology.

[26]  J. Borovička,et al.  Interferon and amantadine in naive chronic hepatitis C: A double‐blind, randomized, placebo‐controlled trial , 2002, Hepatology.

[27]  J. Aslam,et al.  Seroprevalence of the Antibody to Hepatitis C in Select Groups in the Punjab Region of Pakistan , 2001, Journal of clinical gastroenterology.

[28]  R. Wejstål.  Sexual transmission of hepatitis C virus. , 1999, Journal of hepatology.

[29]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[30]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[31]  B. Clarke.  Molecular virology of hepatitis C virus. , 1997, The Journal of general virology.

[32]  H. Thomas,et al.  Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. , 1996, Journal of hepatology.

[33]  P. Couzigou,et al.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. , 1995, The New England journal of medicine.

[34]  C. Bréchot,et al.  Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. , 1995, Annals of internal medicine.

[35]  T. Date,et al.  Differences in the hepatitis C virus genotypes in different countries. , 1993, Journal of hepatology.

[36]  J. Hoofnagle,et al.  Antiviral therapy of hepatitis C--present and future. , 1993, Journal of hepatology.